Oral sessions summaries
Tofacitinib for the treatment of adult patients with ankylosing spondylitis: primary analysis of a phase 3, randomized, double-blind, placebo-controlled study
Expert commentary by Sofia Ramiro, MD, Msc, PhD
ACR Convergence 2020 - Oral session summaries - Abs #L11
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis: 1-year results from a randomized, double-blind, placebo-controlled study with open-label extension
Expert commentary by Sofia Ramiro, MD, Msc, PhD
ACR Convergence 2020 - Oral session summaries - Abs #2023
Secukinumab provides sustained improvements in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations: results from the MAXIMISE trial
Expert commentary by Fabian Proft, MD
ACR Convergence 2020 - Oral session summaries - Abs #0505
Disease-related factors associated to atherosclerotic disease in axial spondyloarthritis. A multicenter study with 806 patients
Expert commentary by Elena Myasoedova, MD, PhD
ACR Convergence 2020 - Oral session summaries - Abs #0448
Predictors of maintaining inactive disease after etanercept withdrawal, and regaining inactive disease status after flare and retreatment, in adults with non-radiographic axial spondyloarthritis: results from RE-EMBARK
Expert commentary by Marina N. Magey, MD
ACR Convergence 2020 - Oral session summaries - Abs #2028
Efficacy of apremilast for the treatment of manifestations of Behçet’s syndrome other than oral ulcers, including skin lesions and arthritis
Expert commentary by Abhijeet Danve, MD, FACP
ACR Convergence 2020 - Oral session summaries - Abs #0512
Characteristics of giant cell arteritis flares after successful treatment with tocilizumab: results from the long-term extension of a randomized controlled phase 3 trial
Expert commentary by Christian Dejaco, MD, PhD, MBA
ACR Convergence 2020 - Oral session summaries - Abs #0516
Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis
Expert commentary by Laura Andreoli, MD, PhD
ACR Convergence 2020 - Oral session summaries - Abs #0988
Efficacy and safety of guselkumab, a monoclonal antibody specific to the p19-subunit of interleukin-23, through week 52 of a phase 3, randomized, double-blind, placebo-controlled study conducted in biologic-naïve patients with active psoriatic arthritis
Expert commentary by Siba P Raychaudhuri, MD
ACR Convergence 2020 - Oral session summaries - Abs #0506
Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs: a double-blind, randomized controlled phase 3 trial
ACR Convergence 2020 - Oral session summaries - Abs #0504
Efficacy and safety of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis in a randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study
Expert commentary by Siba P Raychaudhuri, MD
ACR Convergence 2020 - Oral session summaries - Abs #2027
Integration of clinical and protein markers through machine learning to distinguish patients with psoriasis arthritis from those with psoriasis without psoriatic arthritis
Expert commentary by Siba P Raychaudhuri, MD
ACR Convergence 2020 - Oral session summaries - Abs #0502
Multimorbidity in rheumatoid arthritis, psoriatic arthritis, gout, and osteoarthritis within the Rheumatology Informatics System for Effectiveness (RISE) registry
Expert commentary by Marina N. Magey, MD
ACR Convergence 2020 - Oral session summaries - Abs #2021
The reliability of scoring sonographic entheseal abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) study
Expert commentary by Abhijeet Danve, MD, FACP
ACR Convergence 2020 - Oral session summaries - Abs #2021
Prevalence, incidence, and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older patients with rheumatoid arthritis: a nationwide cohort study
Expert commentary by Richard Conway, MB BCh BAO, PhD
ACR Convergence 2020 - Oral session summaries - Abs #0489
A phase 2b, randomized, double-blind study in patients with rheumatoid arthritis evaluating the safety and efficacy of evobrutinib compared with placebo in patients with an inadequate response to methotrexate
Expert commentary by Jonathan Kay, MD
ACR Convergence 2020 - Oral session summaries - Abs #2012
Non-obese rheumatoid arthritis patients with low low-density lipoprotein have higher coronary atherosclerosis burden, greater plaque progression and cardiovascular event risk
Expert commentary by Elena Myasoedova, MD, PhD
ACR Convergence 2020 - Oral session summaries - Abs #0485
Stable versus tapered and withdrawn treatment with tumor necrosis factor inhibitor in rheumatoid arthritis remission: a randomized, open-label, phase 4, non-inferiority trial
Exert commentary by Kevin Winthrop, MD
ACR Convergence 2020 - Oral session summaries - Abs #2010
Incidence and risk factors for herpes zoster in rheumatoid arthritis patients receiving upadacitinib
Expert commentary by Abhijeet Danve, MD, FACP
ACR Convergence 2020 - Oral session summaries - Abs #1002
Can a Clinical Disease Activity Index based on patient-reported joint counts (PT-CDAI) be used to inform target-based care in telemedicine? An analysis of 2 early RA cohort studies
Expert commentary by Marina N. Magey, MD
ACR Convergence 2020 - Oral session summaries - Abs #0483
